Duprey Lauren Rusckowski 4

What Happened
Lauren Duprey Rusckowski, Chief Transformation Officer at Takeda Pharmaceutical (TAK), received an award of 59,990 restricted stock units (RSUs) on April 27, 2026. The filing reports the RSUs at $0.00 (typical for grant reporting); these RSUs are performance-based and the number awarded was determined by the Compensation Committee based on specified performance metrics.

Key Details

• Transaction date and type: 2026-04-27 — Grant/Award (code A). Report filed 2026-04-28 (timely).
• Reported price/value: $0.00 per share; total reported value $0 (grant reported, not cash proceeds).
• Holdings noted in footnotes: the filing references 146,762 RSUs currently included in holdings; those RSUs vest on July 1, 2026 (100,658), July 1, 2027 (30,488) and July 1, 2028 (15,616).
• Footnote on award: the original award was granted July 1, 2023 and vests as American Depositary Shares based on achievement of core revenue, core operating profit and R&D milestones; on 4/27/2026 the committee determined the performance payout (the 59,990 RSUs reported).
• Filing timeliness: reported the next day — not marked late.

Context
This was an equity award (not an open-market buy or sale). Performance-based RSU grants are contingent on achieving targets and vest over time or upon committee determination; they do not by themselves indicate an insider buying or selling stock. The RSUs represent a right to receive American Depositary Shares if and when vesting conditions are met.